Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ViatrisHAM:VIA -1.40%58 EV-to-EBIT is -91.88 as of Aug. 07, 2026. GuruFocus rates HAM:VIA with a GF Score™ of 58/100 and a GF Value™ of €10.13 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 686 Drug Manufacturers companies, Viatris ranks worse than 145772.45% on this metric.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Viatris's Enterprise Value is €26,899 Mil.
Viatris's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was €-293 Mil. Therefore, Viatris's EV-to-EBIT for today is -91.88.
The historical rank and industry rank for Viatris's EV-to-EBIT or its related term are showing as below:
HAM:VIA'
s EV-to-EBIT Range Over the Past 10 Years
Min: -1447.87 Med: 22.49 Max: 70.34
Current: -91.59
During the past 13 years, the highest EV-to-EBIT of Viatris was 70.34. The lowest was -1447.87. And the median was 22.49.
HAM:VIA's EV-to-EBIT is ranked worse than 100% of 686
companies
in the Drug Manufacturers industry
Industry Median: 15.725
vs HAM:VIA: -91.59
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Viatris's Enterprise Value for the quarter that ended in Mar. 2026 was €23,970 Mil.
Viatris's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-293 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris EV-to-EBIT Related Terms
Viatris EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Viatris's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:VIA vs UTHR, NBIX, ELAN: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Viatris's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viatris EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Viatris's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Viatris's EV-to-EBIT falls into.
Viatris's current Enterprise Value is €26,899 Mil.
Viatris's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-293 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viatris (HAM:VIA) has a EV-to-EBIT of -91.88 as of Aug. 07, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Viatris and its competitors. According to the industry distribution chart, Viatris ranks #999999 out of 686 companies in the Drug Manufacturers industry.
Is Viatris' EV-to-EBIT too high?
Viatris' current EV-to-EBIT is -91.88. Based on the distribution chart, Viatris ranks #999999 out of 686 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Viatris has a GF Score™ of 58/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Viatris' EV-to-EBIT compare to UTHR and NBIX?
According to the Drug Manufacturers industry distribution chart, Viatris ranks #999999 out of 686 companies for EV-to-EBIT. This places Viatris in the lower half of its industry. The industry median EV-to-EBIT is 15.73. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.73, based on 686 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Viatris and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Viatris's current EV-to-EBIT is -91.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viatris stock overvalued right now?
Based on GuruFocus' analysis, Viatris (HAM:VIA) is currently considered Significantly Overvalued. The stock's GF Value™ is €10.13, compared to a current price of €14.96 — trading 47.7% above its estimated fair value. The current EV-to-EBIT is -91.88. Viatris' overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Viatris (HAM:VIA), the current EV-to-EBIT is -91.88 as of Aug. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Viatris (HAM:VIA) Overvalued in 2026?
Based on GuruFocus' analysis, Viatris stock appears to be overvalued.
The current stock price of €14.96 is trading 47.7% above its estimated GF Value™ of €10.13.
GuruFocus considers Viatris to be Significantly Overvalued.
Key valuation signals for HAM:VIA:
EV-to-EBIT: -91.88
GF Value™: €10.13 vs. price of €14.96 (47.7% above fair value)
No single metric tells the full story. See the HAM:VIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
58GF Score
Get the complete analysis for HAM:VIA
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:VIA has been successfully added to your 
